VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, [2], 3, 4, 5 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 22:10:44 08/04/06 Fri
Author: Infection Update
Subject: New challenges for Levofloxacin in the fight against infectious diseases
In reply to: Local Agents 's message, "Daiichi Pharmaceutical Asia , Ltd." on 22:03:09 08/04/06 Fri


Quinolones News

Levofloxacin pharmacokinetics not adversely affected by haemofiltration(July 31, 2006)

Yet another study confirms the effectiveness of levofloxacin-based triple therapy for Helicobacter pylori eradication(July 31, 2006)

High-dose levofloxacin exhibits excellent pharmacokinetics and pharmacodynamics in healthy volunteers.(July 24, 2006)

Oral levofloxacin offers clinically effective and economic prophylaxis for patients undergoing neurosurgery(July 24, 2006)

Indian study confirms the phototoxicity of lomefloxacin, gatifloxacin and sparfloxacin.(July 18, 2006)

High-dose, short-term levofloxacin confirmed as an effective component of triple therapy for Helicobacter pylori eradication(July 18, 2006)

Levofloxacin remains a standard treatment for respiratory tract infections(July 10, 2006)

New controlled release formulation for ciprofloxacin(July 10, 2006)

Levofloxacin is an effective treatment for Legionnaires´ disease(July 3, 2006)

Improving the dosage regimen of levofloxacin for ICU patients(July 3, 2006)

Past News

Quinolones News Archive Selection

A US trial shows that a shorter course of levofloxacin 750 mg for 5 days is just as effective as the longer standard treatment for patients with community-acquired pneumonia(June 5, 2006)

Warning about Telithromycin (KETEK) Liver Problems
The FDA safety reviewers have found that Telithromycin (KETEK) has been linked to 12 cases of liver failure in the U.S. (May 22, 2006)

Gatifloxacin (TEQUIN) taken off the market
The makers of gatifloxacin (TEQUIN) has announced that it would no longer manufacture the drug. Gatifloxacin has been associated with both hypoglycemia and hyperglycemia. (May 8, 2006)





Meeting Calendar: 20 meetings are added and 6 meetings are updated.
June 30, 2006 update (Meeting Calendar)
Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia
December 22, 2005 update (Lectures)
The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis
February 1, 2005 update (Lectures)
Penetration 2006
Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis: Position in Recent Guidelines Hartmut M Lode. 2006: 21-27 (Review)
Antimicrobial Chemotherapy for Legionnaires’ Disease: Levofloxacin Versus Macrolides Rosa Ma Blázquez Garrido. 2006: 28-33 (Review)
Clinical Safety Profile of Fluoroquinolones Keith A Rodvold. 2006: 34-43 (Review)
Levofloxacin for the Treatment of Respiratory Tract Infections Based on Treatment Guidelines Chi-Huei Chiang. 2006: 44-51 (Review)


New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation (Lectures)
Highlights from the 11th International Congress on Infectious Diseases, Cancun, Mexico, March 4-7,2004 (Congress Reports)

Penetration 2005
Levofloxacin for the Treatment of Community-Acquired Pneumonia in the US Based on the Latest Treatment Guidelines John G Bartlett. 2005: 15-20 (Review)
The Experience of Using Levofloxacin in the Emergency Department Sheng-Chuan Hu. 2005: 21-25 (Review)
Clinical Usefulness of Levofloxacin for the Treatment of Urinary Tract Infections Kurt G. Naber, Florian M. E. Wagenlehner. 2005: 26-32 (Review)
The Diagnosis, Treatment and Management of Typhoid Fever and the Role of Fluoroquinolones R.H.H. Nelwan. 2005: 33-38 (Review)
Levofloxacin in the Treatment of Multi-Drug Resistant Streptococcus Pneumoniae Burke A. Cunha. 2005: 39-46 (Review)


Penetration 2004
Role of Levofloxacin in the Treatment of Community-Acquired Pneumonia in Taiwan:
In Vitro Activity and Clinical Efficacy
Po-Ren Hsueh. 2004: 24-28 (Review)
Early Switch Therapy from Intravenous to Oral Levofloxacin Versus Intravenous Ceftriaxone to Oral Cefuroxime Axetil in the Treatment of Moderate to Severe Community-Acquired Pneumonia
Hadiarto Manggunnegoro, Wahyuningsih Soeharno, Adria Rusli. 2004: 29-35 (Review)
Highlights from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA September 14-17, 2003 (Congress Reports)


Website - http://www.infectweb.com/

[ Next Thread | Previous Thread | Next Message | Previous Message ]
[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.